3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
COVID-19
1
Interventions
Cisplatin
14
Pemetrexed
11
pembrolizumab
6
Cyclophosphamide
6
Radiotherapy
3
Interleukin-2
3
Gemcitabine
3
sodium thiosulfate
2
sargramostim
2
defactinib
2
aldesleukin
2
Surgical Procedures, Operative
2
SS1(dsFv)PE38
2
Radiation
2
Platinum
2
Pharmaceutical Preparations
2
Paclitaxel
2
Nivolumab
2
Drug Therapy
2
Depsipeptides
2
Decitabine
2
Celecoxib
2
Carboplatin
2
1,2-diaminocyclohexaneplatinum II citrate
2
osimertinib
1
incomplete Freund's adjuvant
1
entinostat
1
cabozantinib
1
bemcentinib
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Mesothelioma, Malignant
×
bemcentinib
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts